MXCTライブシグナル | Getagraph.comで利益を最大化

買う 137002 min ago

@ $4.78

発行日: 15 2月 2024 @ 02:00

リターン: -2.30%

前回のシグナル: 2月 14 - 00:49

前回のシグナル: 売る

リターン: -0.46 %

Live Chart Being Loaded With Signals

Commentary (18 5月 2024 @ 05:00):

Stats
本日の出来高	270 413
平均出来高	560 692
時価総額	488.22M
EPS	$0 ( 2024-05-08 )
次の収益日	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.34
ATR14	$0.00800 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Johnston John Joseph	Buy	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	100 000	Employee Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	25 000	Common Stock

INSIDER POWER
40.30
Last 100 transactions
Buy: 1 609 082 \| Sell: 743 053

ボリューム相関

長: -0.32 (neutral)

短: -0.57 (weak negative)

Signal:(26.684) Neutral

MaxCyte, Inc. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

MaxCyte, Inc. 相関 - 通貨/商品

-0.15
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.30
( neutral )

MaxCyte, Inc. 財務諸表

Annual	2023
収益:	$41.29M
総利益:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2023
収益:	$41.29M
総利益:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2022
収益:	$44.26M
総利益:	$39.16M (88.48 %)
EPS:	$-0.190

FY	2021
収益:	$33.89M
総利益:	$30.25M (89.24 %)
EPS:	$-0.210

Financial Reports:

No articles found.

MaxCyte, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.